Psoriatic Arthritis

October 01, 2022

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2022.

September 30, 2022

A long-term, post-authorization safety study of adverse events was performed for patients with PsO and/or PsA exposed to apremilast.

September 29, 2022

Although the proportion of women treated with biologics continues to grow, data on treatment recommendations among both physicians and female patients of childbearing age remain limited.

September 28, 2022

“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”

September 27, 2022

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

September 22, 2022

"Dactylitis is considered a core domain of musculoskeletal symptoms in psoriatic arthritis and is important for both patients and physicians when developing treatment strategies.”

September 19, 2022

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

September 17, 2022

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2022.

September 14, 2022

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, frequently co-occurs with the immune-mediated inflammatory condition, psoriasis.

September 13, 2022

In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.